346607-37-2

346607-37-2 structure

Name: Sitafloxacin hydrochloride
Chemical Name: Sitafloxacin hydrochloride
CAS Number: 346607-37-2
Molecular Formula: C₁₉H₁₉Cl₂F₂N₃O₃
Molecular Weight: 446.28
Catalog: Signaling Pathways Anti-infection Bacterial
Create Date: 2022-09-07 09:59:49
Modify Date: 2024-04-09 08:02:20
Sitafloxacin (DU6859a) hydrochloride is a potent, orally active fluoroquinolone antibiotic. Sitafloxacin hydrochloride shows antichlamydial activity and antibacterial activities against a broad range of gram-positive and gram-negative bacteria, including anaerobic bacteria, as well as against atypical pathogens. Sitafloxacin hydrochloride can be used for the research of respiratory tract infection and urinary tract infection[1][2].

Name	Sitafloxacin hydrochloride

Description	Sitafloxacin (DU6859a) hydrochloride is a potent, orally active fluoroquinolone antibiotic. Sitafloxacin hydrochloride shows antichlamydial activity and antibacterial activities against a broad range of gram-positive and gram-negative bacteria, including anaerobic bacteria, as well as against atypical pathogens. Sitafloxacin hydrochloride can be used for the research of respiratory tract infection and urinary tract infection[1][2].
Related Catalog	Research Areas >> Infection Signaling Pathways >> Anti-infection >> Bacterial
In Vitro	Sitafloxacin (DU6859a) hydrochloride shows antibacterial activities with MIC of 0.03, 0.12, 0.06 mg/L for wild-type ATCC 49619, gyrA mutant SP39, parC mutant 1026523 streptococcus pneumoniae stran, respectively[1]. Sitafloxacin (DU6859a) hydrochloride shows antibacterial activities for quinolone-susceptible strains of streptococcus pneumoniae with MIC of 0.03, 0.03 mg/L for EG 00093 and EG 00218 strain, respectively[1]. Sitafloxacin (DU6859a) hydrochloride shows inhibition for DNA gyrase and topoisomerase IV (TopoIV) with >IC50s of 4.38, 3.12 mg/L, respectively[1].
In Vivo	Sitafloxacin (DU6859a; 12.5-100 mg/kg; i.g.; daily for 4 weeks; BALB/c female mice) hydrochloride has antibacterial activity. M. ulcerans cells could be isolated from the inoculated footpads and there was no evidence of footpad swelling[2]. Animal Model: BALB/c female mice[2] Dosage: 12.5, 25, 50 and 100 mg/kg Administration: Oral gavage; daily, for 4 weeks Result: Inhibits the growth of Mycobacterium ulcerans and the M. ulcerans cells
References	[1]. Okumura R, et al. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 2008 Jul;62(1):98-104. [2]. Dhople AM, et al. Activities of sitafloxacin (DU-6859a), either singly or in combination with rifampin, against Mycobacterium ulcerans infection in mice. J Chemother. 2003 Feb;15(1):47-52.

Molecular Formula	C₁₉H₁₉Cl₂F₂N₃O₃
Molecular Weight	446.28

346607-37-2	1406-14-0
6138-79-0	127228-87-9
1406-02-6	929-73-7
1334385-87-3	143851-98-3
56-99-5	186694-02-0
1868961-41-4	1158522-08-7
940364-43-2	2248374-35-6
134104-43-1	131615-57-1
6906-52-1	930439-75-1
1018584-77-4	1252572-60-3